AIM
EBS icon

Advyzon Investment Management’s Emergent Biosolutions EBS Stock Holding History

Advyzon Investment Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,800
Closed -$122K – 580
2025
Q3 		$122K Sell
13,800
-300
-2% -$2.33K 0.02% 477
2025
Q2 		$90K Buy
+14,100
New +$80.7K 0.02% 381

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Advyzon Investment Management's EBS Position: Q4 2025 in Review

Advyzon Investment Management sold out of Emergent Biosolutions (EBS) in Q4 2025, closing a stake of 13,800 shares — an estimated $122K sold.

Advyzon Investment Management first reported a position in EBS in Q2 2025 and held it in 2 quarters. The position peaked at $122K in Q3 2025. 183 funds tracked by Wall St. Rank hold EBS as of Q4 2025.

  • Advyzon Investment Management reported no remaining Emergent Biosolutions position as of Q4 2025 after selling out during the quarter.
  • Advyzon Investment Management sold 13,800 Emergent Biosolutions shares in Q4 2025, an estimated $122K.
  • Advyzon Investment Management first reported a position in Emergent Biosolutions in Q2 2025 and held it in 2 quarters.
  • Advyzon Investment Management's Emergent Biosolutions position peaked at $122K in Q3 2025.
  • 183 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2025.

Based on Advyzon Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.